Yasaman Vali
A5006887486- Liver Disease Diagnosis and Treatment
- Liver Disease and Transplantation
- Liver Diseases and Immunity
- Meta-analysis and systematic reviews
- Hepatitis C virus research
- Reliability and Agreement in Measurement
- Hepatocellular Carcinoma Treatment and Prognosis
- Artificial Intelligence in Healthcare and Education
- Health Systems, Economic Evaluations, Quality of Life
- Pancreatitis Pathology and Treatment
- Neonatal and fetal brain pathology
- Prenatal Substance Exposure Effects
- Trauma and Emergency Care Studies
- Traumatic Brain Injury Research
- Endoplasmic Reticulum Stress and Disease
- Statistical Methods in Clinical Trials
- Hepatitis B Virus Studies
- Frailty in Older Adults
- Academic Writing and Publishing
- Clinical practice guidelines implementation
- Physical Activity and Health
- COVID-19 diagnosis using AI
- Chronic Disease Management Strategies
- Hepatitis Viruses Studies and Epidemiology
- Lipid metabolism and disorders
University of Amsterdam
2020-2025
Amsterdam University Medical Centers
2020-2025
Public Health Service of Amsterdam
2023
Centraal Bureau voor de Statistiek
2022
Amsterdam UMC Location University of Amsterdam
2021
Zero to Three
2020
Tehran University of Medical Sciences
2012-2017
Imperial College London
2017
Brunel University of London
2016
Università Cattolica del Sacro Cuore
2016
Abstract Metabolic dysfunction-associated steatotic liver disease (MASLD), previously known as non-alcoholic fatty disease, encompasses steatosis and metabolic steatohepatitis (MASH), leading to cirrhosis hepatocellular carcinoma. Preclinical MASLD research is mainly performed in rodents; however, the model that best recapitulates human yet be defined. We conducted a wide-ranging retrospective review (metabolic phenotype, histopathology, transcriptome benchmarked against humans) of murine...
ABSTRACT Background and Aims The performance of non‐invasive liver tests (NITs) is known to vary across settings subgroups. We systematically evaluated whether the three NITs in detecting advanced fibrosis patients with metabolic dysfunction‐associated steatotic disease (MASLD) varies age, sex, body mass index (BMI), type 2 diabetes mellitus (T2DM) status or enzymes. Methods Data from 586 adult LITMUS Metacohort participants histologically characterised MASLD were included. diagnostic...
Serum microRNA (miRNA) levels are known to change in non-alcoholic fatty liver disease (NAFLD) and may serve as useful biomarkers. This study aimed profile miRNAs comprehensively at all NAFLD stages.
Detecting NASH remains challenging, while at-risk (steatohepatitis and F≥ 2) tends to progress is of interest for drug development clinical application. We developed prediction models by supervised machine learning techniques, with data biomarkers stage grade patients NAFLD.Learning were collected in the Liver Investigation: Testing Marker Utility Steatohepatitis metacohort (966 biopsy-proven NAFLD adults), staged graded according CRN. Conditions trial definition (NAS ≥ 4;53%), (NASH F...
Introduction Many diagnostic accuracy studies are never reported in full a peer‐reviewed journal. Searching for unpublished may avoid bias due to selective publication, enrich the power of systematic reviews, and thereby help reduce research waste. We assessed searching practices among recent reviews accuracy. Methods extracted data from 100 non‐Cochrane indexed MEDLINE published between October 2017 January 2018 all Cochrane by December 2018, irrespective whether meta‐analysis had been...